^
Association details:
| Biomarker: | EGFR L858R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + tigozertinib (BLU-945) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB123 / 6 - Poorer outcomes in EGFR L858R-driven NSCLC treated with osimertinib may be addressed with novel combination of BLU-945 and osimertinib
Published date:
03/15/2023
Excerpt:
Preclinical studies of combination BLU-945 and osimertinib were performed in L858R-driven BaF3 xenograft models....BLU-945 in combination with osimertinib in a BaF3 L858R xenograft model demonstrated a longer duration of response vs osimertinib monotherapy....Preclinically, BLU-945 in combination with osimertinib increased L858R inhibition, resulting in more durable antitumor activity in L858R xenografts vs osimertinib alone, supporting rationale for combination treatment in patients with L858R mutations.
Source:
Title:
BLU-945 or BLU-701 as single agents versus their combination with osimertinib in EGFR L858R driven tumor models
Published date:
10/12/2022
Excerpt:
BLU-945 in combination with osimertinib resulted in prolonged DOR and survival when compared with BLU-945 or osimertinib as single agents. BLU-701 in combination with osimertinib resulted in superior tumor growth inhibition compared with BLU-701 or osimertinib as single agents....The superior in vivo antitumor activity of BLU-945 or BLU-701 in combination with osimertinib in prolonging the DOR or increasing tumor growth inhibition in these models may have clinical application in improving outcomes of patients with EGFR L858R-driven NSCLC in 1L settings.
